CNTO 328

DRUG5 trials

Sponsors

Centocor, Inc., SWOG Cancer Research Network

Conditions

Carcinoma, Renal CellGiant Lymph Node HyperplasiaKidney CancerLymphoma, Non-HodgkinMultiple MyelomaProstate CancerProstatic Neoplasms

Phase 1

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

CompletedNCT00265135

Centocor, Inc.Carcinoma, Renal Cell

Start: 2003-08-31End: 2006-02-28Updated: 2014-07-03

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

CompletedNCT00401765

Centocor, Inc.Prostatic Neoplasms

Start: 2005-09-30End: 2009-11-30Updated: 2014-05-26

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

CompletedNCT00412321

Centocor, Inc.Giant Lymph Node Hyperplasia, Lymphoma, Non-Hodgkin, Multiple Myeloma

Start: 2005-05-31End: 2011-04-30Updated: 2014-07-01

Phase 2

S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

WithdrawnNCT00311545

SWOG Cancer Research NetworkKidney Cancer

Updated: 2013-02-20

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

CompletedNCT00433446

SWOG Cancer Research NetworkProstate Cancer

Start: 2007-04-30End: 2011-07-31Updated: 2013-02-05

Related Papers

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

Blood Advances2022-07-0633 citations

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.

2020-02-0342 citations